Gilead Sciences, Inc. has entered into a definitive agreement to acquire Forty Seven, Inc. in a transaction valued at approximately $4.9 billion in cash, which was approved by both Gilead and Forty Seven Boards and is anticipated to close during 2Q20, subject to regulatory approvals and other customary closing conditions. The acquisition strengthens Gilead’s immuno-oncology portfolio with the addition of Forty Seven’s investigational lead product candidate, magrolimab. Magrolimab is a monoclon...